Simulations Plus

Simulations Plus Sets Date for 3rd Quarter 2019 Earnings Release and Conference Call

Retrieved on: 
Dienstag, Juli 2, 2019
Technology, Consulting, Professional services, Software, Biotechnology, Pharmaceutical, Health, Simulation software, Simulations Plus, Simulation, Modeling and simulation, Scientific modeling, Biotechnology companies

2019.

Key Points: 
  • 2019.
  • The Company will host a conference call on July 10, 2019, at 4:15 p.m. Eastern Time.
  • A replay of the webcast will be available at the Investors section of the Simulations Plus website following the call.
  • Simulations Plus, Inc., is the premier developer of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.

Simulations Plus Upgrades Flagship GastroPlus

Retrieved on: 
Dienstag, Juni 18, 2019
Technology, Data management, Software, Health, Biotechnology, Pharmaceutical, General Health, Health sciences, Health, Simulation software, Life sciences, Simulations Plus, Physiologically based pharmacokinetic modelling, Pharmacokinetics, Simulation

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.7 of its flagship physiologically based pharmacokinetic (PBPK) modeling platform, GastroPlus .

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.7 of its flagship physiologically based pharmacokinetic (PBPK) modeling platform, GastroPlus .
  • Special thanks to the dedicated scientific team at Simulations Plus and our collaboration partners for all their outstanding efforts.
  • John DiBella , Lancaster division president for Simulations Plus, added: GastroPlus continues to provide researchers, including chemists, DMPK scientists, pharmaceutical developers, and clinical pharmacologists, a proven and flexible PBPK software to support safety and efficacy decisions, first-in-human estimations, formulation optimization, and drug-drug interaction assessments.
  • For over twenty years, Simulations Plus has been dedicated to improving our state-of-the-art tools, and the significant enhancements that are integrated in version 9.7 are just a preview of exciting advancements that will be the foundation for next years entirely new platform release of GastroPlus.

PMDA Adds Licenses of GastroPlus®

Retrieved on: 
Dienstag, Mai 21, 2019
Technology, Software, Health, Biotechnology, Pharmaceutical, General Health, Health, Articles, Pharmaceuticals policy, Pharmaceutical industry, Simulation software, Simulations Plus, Pharmaceutical industry in China, Food and Drug Administration, Biotechnology, European Medicines Agency, Medication

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to add licenses to its GastroPlus software suite.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to add licenses to its GastroPlus software suite.
  • The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have led these efforts, and it is exciting to see PMDA invest in the GastroPlus platform in anticipation of more submissions coming to them for review.
  • Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide.
  • Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Simulations Plus to Present at B. Riley FBR Investor Conference on May 22, 2019

Retrieved on: 
Dienstag, Mai 14, 2019
Technology, Data management, Software, Health, Biotechnology, Clinical trials, Pharmaceutical, Communications, Public relations, Investor relations, General Health, Simulation software, Simulations Plus, Geography of California, Beverly Hills, California, Lluís Companys, FBR, Government of Spain, Spanish politicians

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that Shawn OConnor , chief executive officer, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at 10:30 a.m. (PDT) in Room 8.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that Shawn OConnor , chief executive officer, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at 10:30 a.m. (PDT) in Room 8.
  • The conference will be held on May 22 and 23, 2019, at The Beverly Hilton Hotel in Beverly Hills, California, and is by invitation only.
  • The slides of the Companys presentation will be available at the Resource Center of the Simulations Plus website ( www.simulations-plus.com ).
  • For more information, please contact [email protected] or your B. Riley FBR representative.

FDA Purchases Bundle of ADMET Predictor® Licenses

Retrieved on: 
Dienstag, April 30, 2019
Technology, Software, Health, Biotechnology, Pharmaceutical, FDA, Health, Food and Drug Administration, Simulation software, Simulations Plus, Center for Tobacco Products, Tobacco, Psychoactive drugs, Articles

The purchase was made by the Center for Tobacco Products to support research projects aimed at informing regulatory decision making.

Key Points: 
  • The purchase was made by the Center for Tobacco Products to support research projects aimed at informing regulatory decision making.
  • John DiBella , Lancaster division president for Simulations Plus, said: For many years, the FDA has utilized our software across various departments, including the Office of Clinical Pharmacology, Office of Generic Drugs, and Office of Pharmaceutical Quality.
  • We are thrilled to now see the Center for Tobacco Products incorporate our machine learning technology to support their risk assessment activities as they evaluate tobacco products and ingredients.
  • We look forward to interactions with the FDA staff to understand model performance on their chemicals and identify future advances to ADMET Predictors functionality and workflow.

Simulations Plus Releases ADMET Predictor® Version 9.5

Retrieved on: 
Donnerstag, April 11, 2019
Health, Biotechnology, Pharmaceutical, Communications, Public relations, Investor relations, General Health, Simulation software, Simulations Plus, Medicinal chemistry, ADME, Biotechnology, Simulation, Industries

Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.5 of its flagship machine learning modeling platform, ADMET Predictor .

Key Points: 
  • Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.5 of its flagship machine learning modeling platform, ADMET Predictor .
  • In particular, the ability of chemists to now see how a molecule could be optimized for important ADMET properties tells a story that can be easily communicated across departments as research programs progress.
  • This further establishes our machine learning platform as an industry leader and will be welcomed by clients.
  • Lancaster division president, John DiBella , added: We continue to realize solid growth in the number of companies, from small to large, and regulatory agencies that license ADMET Predictor.

Simulations Plus Reports Record Second Quarter FY2019 Revenue

Retrieved on: 
Dienstag, April 9, 2019
Health, Biotechnology, Pharmaceutical, Communications, Public relations, Investor relations, General Health, Simulation software, Simulations Plus, Simulation

Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its second quarter of fiscal year 2019, the period ended February 28, 2019 (2QFY19).

Key Points: 
  • Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its second quarter of fiscal year 2019, the period ended February 28, 2019 (2QFY19).
  • John Kneisel, chief financial officer of Simulations Plus, added: Second quarter pretax earnings increased 13% over the prior year.
  • A replay of the webcast will be available at the Investors section of the Simulations Plus website following the call.
  • Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Simulations Plus Sets Date for 2nd Quarter 2019 Earnings Release and Conference Call

Retrieved on: 
Dienstag, April 2, 2019
Health, Biotechnology, Pharmaceutical, Communications, Public relations, Investor relations, NASDAQ, Economy of New York City, Conference call, Simulations Plus, Economy of the United States, Finance, Financial markets

Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2019 fiscal year, the period ended February 28, 2019, on Tuesday, April 9, 2019.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2019 fiscal year, the period ended February 28, 2019, on Tuesday, April 9, 2019.
  • The Company will host a conference call on April 9, 2019, at 4:15 p.m. Eastern Time.
  • All interested parties are invited to join the call by registering here .
  • A replay will be available at the Simulations Plus website following the call.

Simulations Plus Releases DDDPlus™ Version 6

Retrieved on: 
Dienstag, Januar 15, 2019
Technology, Software, Health, Biotechnology, Pharmaceutical, Other Science, Science, Simulation software, Simulations Plus, In vitro, Simulation, Scientific modelling, Philosophy of science, Epistemology, Assumption

Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software, DDDPlus .

Key Points: 
  • Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software, DDDPlus .
  • We are especially excited about the improved functionality and synergies between this new release of DDDPlus and GastroPlus.
  • Version 6 will offer users one-of-a-kind approaches that better inform their in vivo predictions and allow them to make formulation development decisions with confidence.
  • An in-depth webinar showcasing the new features in DDDPlus can be streamed on the company website.

Simulations Plus to Present at the 21st Annual Needham Growth Conference

Retrieved on: 
Donnerstag, Januar 10, 2019
Health, Biotechnology, Pharmaceutical, Professional services, Consulting, Communications, Public relations, Investor relations, Other Science, Science, General Health, Simulation software, Simulations Plus, Lotte, Simulation video game

Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn OConnor will present at the 21st Annual Needham Growth Conference in New York City on Wednesday, January 16, 2019, at 8:40 a.m.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn OConnor will present at the 21st Annual Needham Growth Conference in New York City on Wednesday, January 16, 2019, at 8:40 a.m.
  • In addition to his presentation, Mr. OConnor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.
  • A live webcast of the presentation will be accessible from the Events section of the Company's website ( www.simulations-plus.com ).
  • For more information about the conference or to schedule a one-on-one meeting with Mr. OConnor, please contact Hayden IR at [email protected] .